Topiramate (Epilepsy)

Late intrauterine deaths (> 22 weeks)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S8004
R24377		 AlSheikh (Topiramate) (Controls exposed to Lamotrigine, sick), 2020 Stillbirth during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick excluded Adjustment: No 39.00 [0.31;4841.77] C
excluded (control group) 		0/1   0/20 0 1
ref
S8005
R24379		 AlSheikh (Topiramate) (Controls unexposed, sick), 2020 Stillbirth during pregnancy (anytime or not specified) prospective cohort unexposed, sick Adjustment: No 15.00 [0.12;1923.88] C 0/1   0/8 0 1
ref
S6251
R16645		 Arkilo (Topiramate), 2015 Stillbirth during pregnancy (anytime or not specified) retrospective cohort exposed to other treatment, sick Adjustment: No 15.67 [0.22;1102.00] C 0/2   0/24 0 2
ref
Total 2 studies 15.37 [0.63;376.77] 0 3
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF AlSheikh (Topiramate) (Controls unexposed, sick), 2020AlSheikh, 2020 1 15.00[0.12; 1923.88]0143%ROB confusion: criticalROB selection: moderateROB classification: unclearROB missing: unclearROB mesure: moderateROB reporting: moderate Arkilo (Topiramate), 2015Arkilo, 2015 2 15.67[0.22; 1102.00]0257%ROB confusion: criticalROB selection: criticalROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 15.37[0.63; 376.77]-30.950.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Topiramate) (Controls unexposed, sick; 2: Topiramate;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 15.37[0.63; 376.77]-30%NAAlSheikh (Topiramate) (Controls unexposed, sick), 2020 Arkilo (Topiramate), 2015 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 15.00[0.12; 1923.88]-1 -NAAlSheikh (Topiramate) (Controls unexposed, sick), 2020 1 exposed to other treatment, sickexposed to other treatment, sick 15.67[0.22; 1102.00]-2 -NAArkilo (Topiramate), 2015 1 Tags Adjustment   - No  - No 15.37[0.63; 376.77]-30%NAAlSheikh (Topiramate) (Controls unexposed, sick), 2020 Arkilo (Topiramate), 2015 2 All studiesAll studies 15.37[0.63; 376.77]-30%NAAlSheikh (Topiramate) (Controls unexposed, sick), 2020 Arkilo (Topiramate), 2015 20.550.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 8004

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls Out of scale15.00[0.12; 1923.88]-1 -NAAlSheikh (Topiramate) (Controls unexposed, sick), 2020 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls Out of scale23.35[0.96; 566.96]-30%NAAlSheikh (Topiramate) (Controls exposed to Lamotrigine, sick), 2020 Arkilo (Topiramate), 2015 20.510.01.0